Kong Yanan, Yang Lu, Tang Hailin, Lv Ning, Xie Xinhua, Li Jing, Guo Jiaoli, Li Laisheng, Wu Minqin, Gao Jie, Yang Hongjian, Tang Zhonghua, He Jianjun, Zhang Bin, Li Hui, Qiao Youlin, Xie Xiaoming
Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong, China.
PLoS One. 2013 Nov 20;8(11):e81055. doi: 10.1371/journal.pone.0081055. eCollection 2013.
Compared with invasive breast cancer, breast cancer in situ (BCIS) is seldom life threatening. However, an increasing incidence has been observed in recent years over the world. The purpose of our study is to investigate the epidemiological, clinical and pathological profiles of BCIS in Chinese women from 1999-2008.
Four thousand and two hundred-eleven female breast cancer (BC) patients were enrolled in this hospital-based nation-wide and multi-center retrospective study. Patients were randomly selected from seven hospitals in seven representative geographical regions of China between 1999 and 2008. The epidemiological, clinical and pathological data were collected based on the designed case report form (CRF).
There were one hundred and forty-three BCIS cases in four thousand and two hundred-eleven BC patients (3.4%). The mean age at diagnosis was 48.3 years and BCIS peaked in age group 40-49 yrs (39.9%). The most common subtype was ductal carcinoma in situ (DCIS) (88.0%). 53.8% were positive for estrogen receptor (ER). Human epidermal growth factor receptor 2 (HER2) positive status was observed in 23.8% of patients. All patients underwent surgeries and 14.7% of them had breast conservation therapies (BCT) (21/143), but 41.9% accepted chemotherapy (64/143). Much less patients underwent radiotherapy (16.0%, 23/143) and among patients who had BCT, 67% accepted radiotherapy (14/21). Endocrine therapy was taken in 44.1% patients (63/143).
The younger age of BCIS among Chinese women than Western countries and increasing number of cases pose a great challenge. BCT and endocrine therapy are under great needs.
与浸润性乳腺癌相比,原位乳腺癌(BCIS)很少危及生命。然而,近年来全球范围内其发病率呈上升趋势。我们研究的目的是调查1999年至2008年中国女性BCIS的流行病学、临床和病理特征。
本研究为基于医院的全国多中心回顾性研究,纳入了4211例女性乳腺癌(BC)患者。患者于1999年至2008年间从中国七个具有代表性地理区域的七家医院中随机选取。根据设计好的病例报告表(CRF)收集流行病学、临床和病理数据。
4211例BC患者中有143例BCIS病例(3.4%)。诊断时的平均年龄为48.3岁,BCIS在40 - 49岁年龄组达到峰值(39.9%)。最常见的亚型是导管原位癌(DCIS)(88.0%)。53.8%的患者雌激素受体(ER)呈阳性。23.8%的患者观察到人类表皮生长因子受体2(HER2)阳性。所有患者均接受了手术,其中14.7%接受了保乳治疗(BCT)(21/143),但41.9%接受了化疗(64/143)。接受放疗的患者较少(16.0%,23/143),在接受BCT的患者中,67%接受了放疗(14/21)。44.1%的患者接受了内分泌治疗(63/143)。
中国女性BCIS患者年龄比西方国家小,且病例数不断增加,这带来了巨大挑战。对保乳治疗和内分泌治疗的需求很大。